JP2006280263A - Bacillus bifidus cell powder - Google Patents

Bacillus bifidus cell powder Download PDF

Info

Publication number
JP2006280263A
JP2006280263A JP2005103714A JP2005103714A JP2006280263A JP 2006280263 A JP2006280263 A JP 2006280263A JP 2005103714 A JP2005103714 A JP 2005103714A JP 2005103714 A JP2005103714 A JP 2005103714A JP 2006280263 A JP2006280263 A JP 2006280263A
Authority
JP
Japan
Prior art keywords
bifidobacteria
powder
starch
spray
gelatinized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005103714A
Other languages
Japanese (ja)
Inventor
Masayuki Watanabe
正行 渡邊
Hajime Nakajima
肇 中島
Toshimitsu Yoshioka
俊満 吉岡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snow Brand Milk Products Co Ltd
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Priority to JP2005103714A priority Critical patent/JP2006280263A/en
Publication of JP2006280263A publication Critical patent/JP2006280263A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To obtain dry powder comprising Bacillus bifidus cells of good survivability, maintaining probiotic functions that are exerted by the intake of Bacillus bifidus cells including intestine-conditioning activity or intraintestinal harmful bacteria-suppressive activity, immunoregulatory activity, cholesterol level-lowering activity and prophylactic activity. <P>SOLUTION: The Bacillus bifidus cell powder of high survivability is obtained by the following procedure: Ungelatinized starch powder or its suspension and a Bacillus bifidus culture liquid are mixed together so as not to gelatinize into a suspension, which is then spray-dried in fine circular or ellipsoidal droplets through a nozzle or under pressure. When observed with a polarizing microscope, a cross (interference ring) indicating that starch is not gelatinized can be seen. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

本発明は、プロバイオティクス機能を維持する、生残性の良好なビフィズス菌菌体粉末に関する。   The present invention relates to a bifidobacteria cell powder having good survival characteristics that maintains a probiotic function.

ビフィズス菌は、食品の製造に広く利用されており、醗酵乳、乳酸菌飲料等の乳製品を製造する際に用いられている。さらに、近年、腸内有害菌抑制作用、免疫調節作用、コレステロール低下作用、感染防御作用等の生菌体を摂取することによって発揮される生体調節機能であるプロバイオティクス機能が次々と明らかにされており、ビフィズス菌の菌体自体やビフィズス菌培養物等を健康食品や医薬品等の素材として利用するための開発がなされている。また、これらのビフィズス菌は家畜や家禽の飼料に配合して使用されている。これまで家畜や家禽等の健康維持管理を目的に抗生物質が多量に投与され、いわゆる薬剤耐性菌が発生するという問題が発生しているが、プロバイオティクス機能を有するビフィズス菌を投与することによって、家畜や家禽の健康状態を維持したまま、薬剤耐性菌の発生を抑制することができるという報告もなされている。   Bifidobacteria are widely used in the production of foods, and are used when producing dairy products such as fermented milk and lactic acid bacteria beverages. Furthermore, in recent years, probiotic functions, which are bioregulatory functions that are exerted by ingesting live cells such as intestinal harmful bacteria suppression action, immunoregulatory action, cholesterol lowering action, infection defense action, etc. have been revealed one after another. Developments have been made to use bifidobacteria cells themselves or bifidobacteria cultures as materials for health foods and pharmaceuticals. Moreover, these bifidobacteria are used by blending them with livestock and poultry feeds. Until now, there has been a problem that antibiotics have been administered in large quantities for the purpose of health maintenance management of livestock and poultry, and so-called drug-resistant bacteria have occurred, but by administering bifidobacteria with probiotic function There are also reports that the occurrence of drug-resistant bacteria can be suppressed while maintaining the health of livestock and poultry.

ビフィズス菌菌体をヒトや動物に投与する場合、これを粉末化し、タブレット、カプセル、顆粒剤、散剤等として使用している。ビフィズス菌菌体をタブレット、カプセル、顆粒剤、散剤等にする場合、ビフィズス菌菌体粉末と賦形剤や他の成分とを混合する必要があるが、粉末同士を均一に混合しようとするとき、混合する粉末の粒子径が均一でなかったり、粒子形状が異なっていると、いわゆる分級という現象が起こり粉末の均一な分散が出来なくなる。また、カプセル、シームレスカプセル、あるいは粒子形状の小さいソフトカプセル内にビフィズス菌菌体粉末を封入しようとする場合、微小な空間内にビフィズス菌菌体粉末を封入しなければならないが、粉末の粒子形状が円形または楕円形であると、カプセル内にビフィズス菌菌体粉末が均一にかつ効率的に分散する。しかし、ビフィズス菌菌体を凍結乾燥し、機械的に粉砕して調製した粉末の場合、平均粒子径としてはある程度粒子の大きさが揃っていても、その形状が不定形であるので、微小な空間に不定形の粉末を均一にかつ効率的に封入するのは難しいという欠点が見られる。これは打錠機による打錠成型時も同様である。さらに、ブロック状の固形物ができるので、機械的に粉砕する等の工程をさらに行わないと均一な粒子径の粉末ができないという欠点があり、しかも粉砕を行っても、粒子形状が線状となり、円形または楕円形にはならない。   When bifidobacteria cells are administered to humans or animals, they are powdered and used as tablets, capsules, granules, powders, and the like. When bifidobacteria cells are made into tablets, capsules, granules, powders, etc., it is necessary to mix the bifidobacteria cell powder with excipients and other components, but when trying to mix the powders uniformly If the particle diameter of the powder to be mixed is not uniform or the particle shape is different, a so-called classification phenomenon occurs and the powder cannot be uniformly dispersed. In addition, when bifidobacteria cell powder is to be encapsulated in a capsule, seamless capsule, or soft capsule with a small particle shape, the bifidobacteria cell powder must be encapsulated in a small space. When it is round or oval, the bifidobacteria cell powder is uniformly and efficiently dispersed in the capsule. However, in the case of a powder prepared by freeze-drying Bifidobacteria cells and mechanically pulverizing them, the average particle size is irregular even though the particle size is uniform to some extent. There is a drawback that it is difficult to uniformly and efficiently enclose an irregularly shaped powder in the space. The same applies to tableting with a tableting machine. Furthermore, since a block-like solid is formed, there is a disadvantage that a powder with a uniform particle size cannot be obtained unless further steps such as mechanical pulverization are performed, and even if pulverization is performed, the particle shape becomes linear. Does not become round or oval.

一方、噴霧乾燥により得られるビフィズス菌菌体粉末は、デンプン等の賦形剤に取り込まれてその粒子形状が円形または楕円形となり、凍結乾燥等の方法によって乾燥し機械的に粉砕して調製した粒子形状が線状の粉末よりカプセル内にビフィズス菌菌体が均一にかつ効率的に分散するという利点がある。また、噴霧乾燥は試料を凍結し減圧状態で凍結したまま乾燥させる凍結乾燥に比べ、エネルギーや設備に要するコストが格段に安い。
したがって、ビフィズス菌菌体粉末を調製するためには、利用しやすさや調製コストの面から凍結乾燥より噴霧乾燥の方が圧倒的にメリットが多く、噴霧乾燥によるビフィズス菌菌体粉末の調製は、これまでに多くなされてきた。
On the other hand, the bifidobacterial cell powder obtained by spray drying was incorporated into an excipient such as starch and the particle shape became circular or oval, and was prepared by drying and mechanically grinding by a method such as freeze drying. There is an advantage that the bifidobacteria cells are uniformly and efficiently dispersed in the capsule from the powder having a linear particle shape. In addition, spray drying is much cheaper in energy and equipment than freeze drying in which a sample is frozen and dried in a reduced pressure state.
Therefore, in order to prepare bifidobacteria cell powder, spray drying is overwhelmingly more advantageous than freeze-drying in terms of ease of use and preparation cost, and preparation of bifidobacteria cell powder by spray drying is A lot has been done so far.

食品や健康食品、医薬品、飼料への利用が広がっているビフィズス菌菌体ではあるが、このような中、ビフィズス菌菌体の用途を広げる可能性の一つとして、ビフィズス菌菌体自体の生残性を上げようとする試みがなされている。一般的に、プロバイオティクス機能とは、生菌をヒトまたは動物に与えることによって、摂取したヒトまたは動物に対して発揮される有用な生体調節機能を指している。そのため、発酵食品としての発酵乳、発酵乳乳酸菌飲料、乳酸菌飲料においては、商品の規格として生菌数が規定されており、商品の成立条件としてビフィズス菌を含む乳酸菌菌数の維持が求められており、これらの製品中で生菌数を維持することは重要な課題である。
また、生菌数を維持すると同時に、上記のビフィズス菌菌体を摂取することによるプロバイオティクス機能が失活しないようにすることも重要な課題である。
Bifidobacteria cells are widely used in foods, health foods, pharmaceuticals, and feeds. However, as one of the possibilities for expanding the use of Bifidobacteria cells, Attempts have been made to increase the persistence. In general, the probiotic function refers to a useful bioregulatory function that is exerted on an ingested human or animal by supplying live bacteria to the human or animal. Therefore, in fermented milk, fermented milk lactic acid bacteria beverages, and lactic acid bacteria beverages as fermented foods, the number of viable bacteria is defined as a product standard, and the maintenance of the number of lactic acid bacteria including bifidobacteria is required as a condition for product establishment. Therefore, maintaining the viable count in these products is an important issue.
It is also important to keep the probiotic function from being inactivated by maintaining the viable cell count and at the same time ingesting the above-mentioned bifidobacteria cells.

しかしながら、ビフィズス菌は、酸、温度、pH、塩濃度、水分活性、胆汁酸等の各種の環境ストレスに弱いものが多く、実際に上記製品に使用する場合には用途が限定される場合が多い。前述のように、ビフィズス菌菌体粉末の粒子形状やコストの面では凍結乾燥より噴霧乾燥の方がメリットが多いが、ビフィズス菌は熱に弱く、噴霧乾燥の際に、液体を微粒子化し熱風にさらされることによって生残率が低下し、ビフィズス菌菌体が有するプロバイオティクス機能が損なわれる場合が多かった。   However, many Bifidobacteria are vulnerable to various environmental stresses such as acid, temperature, pH, salt concentration, water activity, bile acid, etc., and their use is often limited when actually used in the above products. . As mentioned above, spray drying is more advantageous than freeze drying in terms of particle shape and cost of bifidobacteria cell powder, but bifidobacteria are weaker to heat, and when spray drying, liquid is made into fine particles and turned into hot air. As a result, the survival rate decreased, and the probiotic function of bifidobacteria was often impaired.

乳酸菌等の菌体粉末を得る一般的な方法として、デンプン糊化菌製剤法を挙げることが出来る(例えば、非特許文献1参照。)。これは菌体懸濁液に糊化したデンプンを賦形剤として加え、さらにL-システイン、L-リジン、グルタミン酸Na等の保護剤を加えて減圧乾燥させる方法である。この方法によると、生菌数は減圧乾燥法で7.2log/g(対照実験として、凍結乾燥で9.6log/g、噴霧乾燥で8.4log/g)であったとしている。この発明では賦形剤としてデンプンを使用することが示されているものの、全て「糊化したデンプン」が用いられている。   As a general method for obtaining bacterial powder such as lactic acid bacteria, there can be mentioned a starch gelatinized bacterial preparation method (for example, see Non-Patent Document 1). In this method, gelatinized starch is added to the cell suspension as an excipient, and a protective agent such as L-cysteine, L-lysine or sodium glutamate is added and dried under reduced pressure. According to this method, the viable cell count was 7.2 log / g by the vacuum drying method (as a control experiment, 9.6 log / g by freeze-drying and 8.4 log / g by spray-drying). Although this invention shows the use of starch as an excipient, all "gelatinized starch" is used.

また、噴霧乾燥機の噴霧ノズルを改良することによって、乳酸菌及びビフィズス菌懸濁液の粒子径が10μm以下になるようにサブミクロン化し、噴霧乾燥することによって、生残率が向上した乳酸菌及びビフィズス菌菌体粉末を調製することが可能となったという報告がある(例えば、特許文献1参照。)。この発明の骨子は、乳酸菌及びビフィズス菌懸濁液の粒子径を、噴霧ノズルを工夫することによってサブミクロン化することである。この発明の明細書中でも菌体液に配合することができる結合剤の一つとしてα化デンプンが示されているものの、これは「糊化したデンプン」である。   Also, by improving the spray nozzle of the spray dryer, the lactic acid bacteria and bifidobacteria suspension were submicronized so that the particle diameter of the suspension of lactic acid bacteria and bifidobacteria was 10 μm or less, and the survival rate was improved by spray drying. There is a report that it has become possible to prepare fungus powder (see, for example, Patent Document 1). The gist of the present invention is to make the particle diameter of the suspension of lactic acid bacteria and bifidobacteria submicron by devising a spray nozzle. In the specification of the present invention, pregelatinized starch is shown as one of the binders that can be incorporated into the cell fluid, but this is “gelatinized starch”.

さらに、ビフィズス菌菌体の噴霧乾燥条件について、糊化したデンプンとビフィズス菌菌体とを混合し噴霧乾燥したところ、デンプンのネットワークの中にビフィズス菌菌体が取り込まれる形になった場合に生残性が良好であったという報告がある(例えば、非特許文献2参照。)。この報告によると、ビフィズス菌の生残率が、糊化したデンプンを使用しない場合には10%程度であったのに対し、糊化したデンプンを添加して噴霧乾燥した場合は30%程度に上昇したと記載されている。   Furthermore, regarding the spray drying conditions for Bifidobacteria cells, gelatinized starch and Bifidobacteria cells were mixed and spray-dried, and this was generated when Bifidobacteria cells were incorporated into the starch network. There is a report that the persistence was good (for example, see Non-Patent Document 2). According to this report, the survival rate of bifidobacteria was about 10% when gelatinized starch was not used, but about 30% when gelatinized starch was added and spray-dried. It is stated that it has risen.

このようにビフィズス菌の生残率の低下を防ぐ種々の方法が開示されているものの、生残率が著しく向上したという結果を示しているものはなく、また噴霧ノズルの改良等による噴霧乾燥機自体の変更や工程の変更を伴ったりするので煩雑である。
特許第3363438号公報 光岡知足編、ビフィズス菌の研究、日本ビフィズス菌センター刊、(1994) K.O'Riordan、D.Andrews、P.Conway、J.Appl.Microbiol.91: 1059-66 (2001)
Although various methods for preventing the decrease in the survival rate of bifidobacteria have been disclosed in this way, none of the methods show a result that the survival rate has been significantly improved. It is complicated because it involves changes in itself and processes.
Japanese Patent No. 3363438 Mitsuoka Chitose, Bifidobacteria research, published by Nihon Bifidobacteria Center, (1994) K. O'Riordan, D.C. Andrews, P.A. Conway, J.A. Appl. Microbiol. 91: 1059-66 (2001)

本発明は、整腸作用や腸内有害菌抑制作用、免疫調節作用、コレステロール低下作用、感染防御作用等の、ビフィズス菌菌体を摂取することによって発揮されるプロバイオティクス機能を維持する、生残性が良好なビフィズス菌菌体を含有する乾燥粉末を得ることを課題とする。
また、ビフィズス菌菌体粉末の粒子径が不均一であったり粒子形状が異なると、他の成分と混合する場合に分級が起こり均一な分散が出来なくなったり、また、カプセル内に封入しようとする場合及び打錠成型時に、微小な空間に不定形の粉末を均一にかつ効率的に封入するのは難しいという欠点を解決することを課題とする。
The present invention maintains a probiotic function that is exhibited by ingesting bifidobacterial cells such as intestinal regulation, intestinal harmful bacteria suppression, immunoregulatory, cholesterol lowering, and infection protection. It is an object of the present invention to obtain a dry powder containing bifidobacteria having good persistence.
In addition, if the particle size of the Bifidobacteria cell powder is non-uniform or the particle shape is different, classification may occur when mixing with other components, and uniform dispersion will not be possible, and attempts to encapsulate in the capsule It is an object of the present invention to solve the disadvantage that it is difficult to uniformly and efficiently encapsulate an irregularly shaped powder in a minute space when molding and tableting.

発明者らは鋭意研究を行った結果、ビフィズス菌培養液と、糊化していないデンプン粉末またはデンプンの水懸濁液とを糊化しないように懸濁状態で混合することにより、不定形のデンプン破砕物を含有しない、粒子径が均一であり一定の粒子形をもった、生残性が良好なビフィズス菌菌体粉末を効率よく得ることに成功し、本発明を完成させるに至った。
また、本発明はプロバイオティクス機能を保持するビフィズス菌菌体を含有する乾燥粉末を調製する際に、ビフィズス菌の培養液と、糊化していないデンプンの粉末または懸濁液とを、デンプンが糊化しないように混合して懸濁液とし、この懸濁液を噴霧乾燥することを特徴とする生残性が良好なビフィズス菌菌体粉末の製造方法である。
従来技術として、糊化したデンプンの粉末または懸濁液と乳酸菌培養液とを混合して噴霧乾燥することは開示されているが、糊化していないデンプンの粉末または懸濁液とビフィズス菌培養液とを糊化しないように懸濁して噴霧乾燥する本発明の方法により、粒子径が均一であり一定の粒子形をもつ粉末が得られるという噴霧乾燥のメリットを維持しながら、生残性が減少するという噴霧乾燥のデメリットを防止するという格別の効果を生ずる。
As a result of intensive studies, the inventors of the present invention have found that by mixing a bifidobacteria culture solution and an ungelatinized starch powder or an aqueous suspension of starch in a suspended state so as not to gelatinize, an irregular starch The present invention was completed by successfully obtaining a bifidobacteria cell powder having a uniform particle size, a uniform particle shape, and a good survival rate that does not contain crushed materials.
Further, in the present invention, when preparing a dry powder containing bifidobacteria cells having a probiotic function, a culture solution of bifidobacteria and a non-gelatinized starch powder or suspension are used. This is a method for producing a bifidobacteria cell powder having good survival characteristics, characterized in that the suspension is mixed so as not to gelatinize, and the suspension is spray-dried.
As a prior art, it is disclosed that powdered gelatin powder or suspension and lactic acid bacteria culture liquid are mixed and spray-dried. However, starch powder or suspension without gelatinization and Bifidobacterium culture liquid are disclosed. The method of the present invention, in which the powder is suspended and spray-dried so as not to gelatinize, reduces the survivability while maintaining the merit of spray-drying, in which a powder having a uniform particle size and a constant particle shape is obtained. This produces a special effect of preventing the disadvantages of spray drying.

デンプンを水中に懸濁し加熱すると、デンプン粒は吸水して次第に膨張し、加熱を続けると最終的にはデンプン粒は崩壊し溶解する。この現象を糊化と呼んでいる。デンプンはその骨格をなす水に難溶性のアミロペクチンと、これに包蔵される水溶性のアミロースから構成されており、デンプンの糊化は結晶構造をとっているアミロペクチンの隙間に水分子が入り込むことでその構造が緩み、各枝が水中に広がることによって起こるものと考えられている。糊化温度はデンプンの原料により異なるが、通常60〜80℃である。本発明は、デンプンと水とが糊化しないよう糊化温度以下の室温(25℃前後)で混合してデンプンが糊化していない懸濁液とし、これにビフィズス菌の菌体培養液を混合して噴霧乾燥することを特徴とする。糊化していないデンプン粉末とビフィズス菌の菌体培養液を混合して噴霧乾燥しても良い。このようにして得られた本発明のビフィズス菌菌体粉末を光学顕微鏡で観察すると、ビフィズス菌体は観察されず、デンプン粉末及びデンプンに囲まれたビフィズス菌菌体粉末の二粉体が混合した状態となっている。この状態で水を加えるとビフィズス菌体が観察された。したがって、ビフィズス菌体の表面はデンプンに覆われているものと考えられる。   When starch is suspended in water and heated, the starch granules absorb water and gradually expand, and when heating is continued, the starch granules eventually disintegrate and dissolve. This phenomenon is called gelatinization. Starch is composed of amylopectin, which is sparingly soluble in water, which forms the skeleton, and water-soluble amylose, which is contained in the starch. Gelatinization of starch is caused by water molecules entering the gaps between the amylopectin in the crystalline structure. It is thought that the structure is loosened and each branch spreads into the water. The gelatinization temperature varies depending on the starch raw material, but is usually 60 to 80 ° C. In the present invention, the starch and water are mixed at room temperature (about 25 ° C.) below the gelatinization temperature to obtain a suspension in which starch is not gelatinized, and this is mixed with a cell culture solution of Bifidobacterium. And spray drying. Non-gelatinized starch powder and Bifidobacterium cell culture solution may be mixed and spray-dried. When the bifidobacteria cell powder of the present invention obtained as described above was observed with an optical microscope, no bifidobacteria cell was observed, and two powders of starch powder and bifidobacteria cell powder surrounded by starch were mixed. It is in a state. When water was added in this state, bifidobacteria were observed. Therefore, it is considered that the surface of the bifidobacteria is covered with starch.

また、本発明は、糊化していないデンプンの粉末または懸濁液とビフィズス菌の培養液とを糊化しないように混合して懸濁液とし、この懸濁液をノズルや圧力で微細な円形または楕円形の液滴にして噴霧乾燥を行うため、ビフィズス菌菌体粉末の粒子径が正規分布である上、光学顕微鏡で観察した場合、デンプン粉末及びデンプンに覆われたビフィズス菌菌体粉末は、不定形のデンプン破砕物を含有せず、いずれもほぼ球形の粒子からなっている。本発明のビフィズス菌菌体粉末の形状は、糊化したデンプンと混合して噴霧乾燥する従来方法のものとほぼ同様であるが、本発明のビフィズス菌菌体粉末を偏光顕微鏡で観察すると、ビフィズス菌菌体粉末のうちデンプン粉末は、デンプンが糊化していないことを示す特徴的な十字(干渉輪)を見ることができる。   The present invention also provides a non-gelatinized starch powder or suspension and a bifidobacteria culture solution mixed so as not to be gelatinized, and this suspension is finely rounded with a nozzle or pressure. Or, in order to spray-dry into elliptical droplets, the particle size of the bifidobacteria cell powder is a normal distribution, and when observed with an optical microscope, the starch powder and the bifidobacteria cell powder covered with starch are They do not contain irregular shaped starch fragments, and all consist of almost spherical particles. The shape of the bifidobacteria cell powder of the present invention is almost the same as that of the conventional method in which it is mixed with gelatinized starch and spray-dried. When the bifidobacteria cell powder of the present invention is observed with a polarizing microscope, the bifidobacteria cell powder is Among the fungus body powders, the starch powder can have a characteristic cross (interference ring) indicating that the starch is not gelatinized.

ビフィズス菌懸濁液を糊化したデンプンと混合して噴霧乾燥した従来の方法により得られたビフィズス菌粉末を光学顕微鏡で観察したところ、本発明の糊化していないデンプンと混合したビフィズス菌粉末と同様に、ビフィズス菌体は観察されず、この状態で水を加えると菌体が観察された。形状も本発明のビフィズス菌菌体粉末とほぼ同様であるが、偏光顕微鏡で観察すると糊化したデンプンと混合して噴霧乾燥したものは、十字(干渉輪)を見ることができない。   The bifidobacteria powder obtained by the conventional method obtained by mixing the bifidobacteria suspension with gelatinized starch and spray-drying was observed with an optical microscope. Similarly, the bifidobacteria were not observed, and the cells were observed when water was added in this state. The shape is almost the same as that of the bifidobacteria cell powder of the present invention, but when observed with a polarizing microscope, the cross-linked (interference ring) cannot be seen when the mixture is spray-dried by mixing with gelatinized starch.

本発明によって製造したビフィズス菌の粉末は、凍結乾燥によってビフィズス菌を粉末化し、機械的な粉砕工程を経て、糊化していないデンプンと混合、または、凍結乾燥によってビフィズス菌を粉末化した後、糊化していないデンプンと混合し機械的な粉砕を行った粉末とは、前述のように光学顕微鏡で観察することによって線状粉末か、球形又は楕円形であるかの相違を確認することができる。
また、ビフィズス菌懸濁液を糊化したデンプンと混合して噴霧乾燥した従来方法により得られたものとは、前述のように偏光顕微鏡によって十字(干渉輪)の有無を観察することによって異なることを確認することができる。
The bifidobacteria powder produced according to the present invention is powdered by freeze-drying, mixed with starch that has not been gelatinized through a mechanical grinding process, or powdered by freeze-drying and then pasteed. The difference between the powder mixed with non-converted starch and mechanically pulverized can be confirmed by observation with an optical microscope as described above, whether it is linear powder, spherical or elliptical.
Moreover, it differs from what was obtained by the conventional method which mixed the Bifidobacterium suspension with gelatinized starch and was spray-dried by observing the presence or absence of a cross (interference ring) with a polarizing microscope as described above. Can be confirmed.

本発明により得られるビフィズス菌菌体粉末は次のような効果を奏する。
(1)糊化していないデンプンを用いて噴霧乾燥したビフィズス菌菌体粉末は、糊化したデンプンを用いて噴霧乾燥したビフィズス菌菌体粉末と比較して生残性に優れている。
(2)凍結乾燥に比べ、ビフィズス菌菌体粉末の粒子径が均一で粒子形も同一であるので、他の成分と混合する場合に生ずる分級が起こらず、均一な分散が出来る。また、カプセル及び錠剤内にビフィズス菌菌体粉末を封入しようとする場合、カプセル及び錠剤内の微小な空間にビフィズス菌の菌体を均一かつ効率的に分散させることができる。
(3)凍結乾燥に比べ、エネルギーや設備に要するコストが格段に安い噴霧乾燥により、ビフィズス菌菌体粉末を得ることができる。
(4)凍結乾燥で調製した場合には、ブロック状の固形物ができるので、機械的に粉砕等の工程をさらに行わないと均一な粒子径の粉末ができないが、本発明は噴霧乾燥だけで不定形のデンプン破砕物を含有しない、均一な粒子径の粉末を得ることができる。
(5)噴霧ノズルの改良や減圧乾燥等の方法によらずとも、通常の噴霧乾燥装置を用いて、粒子径が均一で粒子形状も同一であるビフィズス菌菌体粉末を得ることができる。
The bifidobacteria cell powder obtained by the present invention has the following effects.
(1) The bifidobacteria cell powder spray-dried using the non-gelatinized starch is excellent in survivability compared with the bifidobacteria cell powder spray-dried using the gelatinized starch.
(2) Compared to freeze-drying, the particle size of the bifidobacteria cell powder is uniform and the particle shape is the same, so classification that occurs when mixed with other components does not occur and uniform dispersion can be achieved. Moreover, when it is going to enclose bifidobacteria cell powder in a capsule and a tablet, the cell of a bifidobacteria can be uniformly and efficiently disperse | distributed to the micro space in a capsule and a tablet.
(3) Bifidobacteria cell powder can be obtained by spray drying, which requires much less energy and facilities than lyophilization.
(4) When it is prepared by freeze-drying, a block-like solid is formed, so that powder with a uniform particle size cannot be obtained unless mechanical grinding and other steps are further performed. It is possible to obtain a powder having a uniform particle size which does not contain irregular shaped starch fragments.
(5) A bifidobacteria cell powder having a uniform particle size and the same particle shape can be obtained using a normal spray drying apparatus, regardless of a method such as improvement of a spray nozzle or drying under reduced pressure.

本発明に使用するビフィズス菌としては、発酵乳に使用されているビフィドバクテリウム・ロンガム(Bifidobacterium longum)、ビフィドバクテリウム・ブレーベ(B. breve)、ビフィドバクテリウム・アニマリス(B. animalis)、ビフィドバクテリウム・シュードロンガム(B. pseudolongum)等を挙げることができる。しかし、使用するビフィズス菌は、これらの菌種に限定されるものではない。   Bifidobacteria used in the present invention include Bifidobacterium longum, B. breve, and B. animalis used in fermented milk. ), B. pseudolongum, and the like. However, the bifidobacteria to be used is not limited to these species.

本発明に使用するビフィズス菌は、乳培地、乳成分を含む培地、半合成培地等種々の培地を用いて培養することができる。このような培地としては、脱脂粉乳を還元して加熱殺菌した還元脱脂乳培地、BL培地、MRS培地等を例示することができる。また、乳や、大豆等の植物原料や、これらに酵母エキス、ペプトン、ビタミン、ミネラル等の適当な栄養源を加えたり、タンパク質分解酵素を作用させたりして調製した液体培地で、これらのビフィズス菌を培養する。   The bifidobacteria used in the present invention can be cultured using various media such as a milk medium, a medium containing milk components, and a semi-synthetic medium. Examples of such a medium include reduced skim milk medium, BL medium, MRS medium and the like obtained by reducing skim milk powder and heat sterilization. In addition, these bifidos can be used in plant materials such as milk and soybeans, and in liquid media prepared by adding appropriate nutrient sources such as yeast extract, peptone, vitamins, minerals, etc., or by causing proteolytic enzymes to act on them. Incubate the fungus.

培養方法として、通常の液体培地、液体培地の上層を不活性ガスや二酸化炭素で置換したもの、pHを一定にした中和培養や回分培養及び連続培養等、さらには、適当な分画サイズを有する分離膜を使用して、ビフィズス菌の培養生成物である乳酸と酢酸を除去した培養を挙げることが出来るが、菌体が良好に生育する条件であれば、培養方法はこれらの方法に特に限定されるものではない。   Culture methods include normal liquid media, those in which the upper layer of the liquid media is replaced with inert gas or carbon dioxide, neutralization culture with a constant pH, batch culture, continuous culture, etc., and an appropriate fraction size. Can be mentioned by removing the lactic acid and acetic acid which are the culture products of bifidobacteria using the separation membrane, but the culture method is particularly limited to these methods as long as the cells grow well. It is not limited.

培養終了後、菌体培養液を、糊化していないデンプンの粉末または懸濁液とデンプンが糊化しないよう十分混合してデンプンが沈殿しないうちに噴霧乾燥に供する。糊化していないデンプン懸濁液とはデンプン粉末を水または糊化する温度以下の温水に混合したものである。また、遠心分離や膜分離によって適当な濃度まで濃縮した菌体培養液、または菌体培養液を生理食塩水や滅菌水等適当な洗浄液で適当な回数、好ましくは1〜3回、洗浄した菌体培養液を、糊化していないデンプンの粉末または懸濁液とデンプンが糊化しないよう十分混合してデンプンが沈殿しないうちに噴霧乾燥することもできる。さらに、菌体を洗浄して適当な噴霧乾燥保護剤と混合した後に、糊化していないデンプンの粉末または懸濁液とデンプンが糊化しないよう十分混合してデンプンが沈殿しないうちに噴霧乾燥することもできる。   After completion of the culture, the cell culture solution is sufficiently mixed with starch powder or suspension not gelatinized so that the starch does not gelatinize, and is subjected to spray drying before the starch precipitates. Non-gelatinized starch suspension is a mixture of starch powder in water or warm water below the gelatinization temperature. In addition, a bacterial cell culture solution concentrated to an appropriate concentration by centrifugation or membrane separation, or a bacterial cell that has been washed an appropriate number of times, preferably 1 to 3 times, with an appropriate washing solution such as physiological saline or sterilized water. The body culture solution can also be spray-dried before the starch precipitates by mixing well with non-gelatinized starch powder or suspension so that the starch does not gelatinize. After washing the cells and mixing with a suitable spray-drying protective agent, mix well with non-gelatinized starch powder or suspension to prevent starch from gelatinizing and spray-dry before starch precipitates You can also.

本発明に使用するデンプンは、特に限定されるものではなく、馬鈴薯、甘藷、玉蜀黍、小麦、米、タピオカ等、広く使用されているデンプンであれば、どのような由来のものでも使用することができる。また、これらのデンプンを単独で、または混合して使用することもできる。   The starch used in the present invention is not particularly limited, and any starch may be used as long as it is widely used, such as potato, sweet potato, onion, wheat, rice, tapioca. it can. These starches can be used alone or in combination.

噴霧乾燥の条件としては、噴霧圧力50〜200kPa、熱風温度60〜150℃、排風温度30〜120℃が好ましい。噴霧時のノズルとしては、遠心型ノズル、二流体ノズル等を例示することができるが、通常の噴霧乾燥に使用されるものであれば、特に限定されるものではない。   The spray drying conditions are preferably a spray pressure of 50 to 200 kPa, a hot air temperature of 60 to 150 ° C, and an exhaust air temperature of 30 to 120 ° C. Examples of the nozzle for spraying include a centrifugal nozzle and a two-fluid nozzle, but are not particularly limited as long as they are used for normal spray drying.

本発明により得られる粉末に含まれるビフィズス菌の生菌数は通常1×108個/gから5×1013個/gであり、望ましくは1×1010個/gから5×1012個/g である。 The viable count of bifidobacteria contained in the powder obtained according to the present invention is usually 1 × 10 8 cells / g to 5 × 10 13 cells / g, preferably 1 × 10 10 cells / g to 5 × 10 12 cells. / g.

本発明の糊化していないデンプンを用いて噴霧乾燥したビフィズス菌菌体粉末は、糊化したデンプンを用いて噴霧乾燥したビフィズス菌菌体粉末と比較して生残性に優れている。本発明では、ビフィズス菌の培養液と、糊化していないデンプンの粉末または懸濁液とを、デンプンが糊化しないように十分混合するが、噴霧乾燥時に一部のデンプンは糊化し、ビフィズス菌を取り囲んでビフィズス菌表面を覆う。糊化していないデンプンを用いて噴霧乾燥した方が生残性に優れているのは、糊化していないデンプンを用いて噴霧乾燥する際に、一部のデンプン粒が糊化して菌体を取り囲む際に菌体に加えられる熱がデンプンの糊化に使用され、菌体の熱によるダメージが少ないためと考えられる。一方、従来方法である糊化したデンプンを用いて噴霧乾燥した場合、デンプンは既に糊化しているので、噴霧乾燥による熱が直接菌体に加わり、菌体が熱によるダメージを受けて生残性が低くなるものと考えられる。   The bifidobacteria cell powder spray-dried using the non-gelatinized starch of the present invention is superior in viability to the bifidobacteria cell powder spray-dried using the gelatinized starch. In the present invention, the culture solution of bifidobacteria and the non-gelatinized starch powder or suspension are sufficiently mixed so that the starch does not gelatinize. To cover the surface of bifidobacteria. When spray-drying with non-gelatinized starch, it is better for survival. When spray-drying with non-gelatinized starch, some starch granules are gelatinized to surround the cells. This is probably because the heat applied to the cells is used for gelatinization of the starch, and the cells are less damaged by the heat. On the other hand, when spray-dried using gelatinized starch, which is a conventional method, starch has already been gelatinized, so heat from spray-drying is directly applied to the cells, and the cells are damaged by heat and survive. Is considered to be low.

本発明により得られたビフィズス菌菌体粉末は、そのままの状態でプロバイオティクス機能を持つ健康食品として利用することができるし、また、糖衣錠やタブレット等の錠剤、粉剤、顆粒剤、カプセル剤等の形態に加工して利用することも可能である。
また、本発明のビフィズス菌菌体粉末は、単独であるいは乳酸菌と混合してスターターとして乳に添加して乳酸発酵させて調製した発酵乳や、発酵ミックスにこれらの粉末を添加して乳酸発酵させたものに用いることができる。さらに、他の乳製品、食肉製品、水産練製品、デザート類、ドレッシング類、健康食品類、麺類、飲料等の様々な飲食品に利用可能である。
さらにまた、本発明は、牛、豚、鶏等の家畜の飼料や、犬、猫等のペットフードに添加して利用することができる。また、サイレージ発酵を促進させるためのスターターとして利用することも可能である。
The bifidobacteria cell powder obtained by the present invention can be used as it is as a health food having a probiotic function, and tablets such as sugar-coated tablets and tablets, powders, granules, capsules, etc. It is also possible to process and use it.
In addition, the bifidobacteria cell powder of the present invention is fermented milk prepared by adding lactic acid bacteria to a milk as a starter alone or mixed with lactic acid bacteria, and fermented milk prepared by adding these powders to a fermentation mix. Can be used for Furthermore, it can be used for various dairy products, meat products, marine products, desserts, dressings, health foods, noodles, beverages and other various foods and drinks.
Furthermore, the present invention can be used by being added to livestock feed such as cattle, pigs and chickens and pet food such as dogs and cats. It can also be used as a starter for promoting silage fermentation.

以下に本発明のビフィズス菌菌体粉末に関し、実施例及び試験例により詳細に説明するが、これらは単に例示するのみであり、本発明はこれらによって何ら限定されるものではない。   Hereinafter, the bifidobacteria cell powder of the present invention will be described in detail with reference to Examples and Test Examples, but these are merely illustrative, and the present invention is not limited thereto.

ビフィドバクテリウム・ロンガムFERM P-10657株をBL培地(光岡知足編、ビフィズス菌の研究、日本ビフィズス菌センター刊、1994)で37℃、16時間静置培養し、連続式遠心分離機により10倍に濃縮した。この培養濃縮液と等量の糊化していない10%タピオカデンプン懸濁液を25℃で糊化しないように混合し、噴霧乾燥機にて入口温度100℃、出口温度50℃で噴霧乾燥し、本発明のビフィズス菌菌体粉末を得た。粉末中の生菌数は1.4×1011個/gであった。 Bifidobacterium longum FERM P-10657 strain was cultivated at 37 ° C for 16 hours in BL medium (Mitsuoka Chichiho, edited by Bifidobacterium, published by Nihon Bifidobacteria Center, 1994). Concentrated twice. This culture concentrate and an equal amount of non-gelatinized 10% tapioca starch suspension are mixed so as not to be gelatinized at 25 ° C., and spray-dried at an inlet temperature of 100 ° C. and an outlet temperature of 50 ° C. in a spray dryer, A Bifidobacterium cell powder of the present invention was obtained. The number of viable bacteria in the powder was 1.4 × 10 11 cells / g.

[試験例1]
イソプロパノール中に実施例1で得られたビフィズス菌菌体粉末を懸濁し、レーザー粒度分布測定装置(島津SALD-2000J)で粉末の粒子径分布を測定した。コントロールとして、培養濃縮液に70℃で混合して糊化させた同量の10%タピオカデンプン懸濁液と混合し、噴霧乾燥機にて実施例1と同一条件で噴霧乾燥して得られたビフィズス菌菌体粉末の粒子径分布を測定した。
結果を図1に示す。本発明のビフィズス菌菌体粉末は正規分布を示している。コントロールとして糊化したデンプン懸濁液を用いたビフィズス菌菌体粉末の粒子径分布も正規分布を示した。
光学顕微鏡で観察した場合、本発明のビフィズス菌菌体粉末は、ほぼ球形の粒子のみからなっており、凍結乾燥等の液滴を調製しない方法で乾燥した粉末を機械的に微粒子化した時に見られる線状の不定形な破砕物は含まれていなかった。さらに、菌体粉末を偏光顕微鏡で観察するとデンプンが糊化していないことを示す特徴的な十字(干渉輪)を見ることができた。コントロールとして糊化したデンプン懸濁液を用いたビフィズス菌菌体粉末は、形状は本発明のものとほぼ同じであるが、十字(干渉輪)を見ることができなかった。
[Test Example 1]
The bifidobacteria cell powder obtained in Example 1 was suspended in isopropanol, and the particle size distribution of the powder was measured with a laser particle size distribution analyzer (Shimadzu SALD-2000J). As a control, it was mixed with the same amount of 10% tapioca starch suspension mixed at 70 ° C. and gelatinized with the culture concentrate, and spray-dried under the same conditions as in Example 1 in a spray dryer. The particle size distribution of the bifidobacteria cell powder was measured.
The results are shown in FIG. The bifidobacteria cell powder of the present invention shows a normal distribution. The particle size distribution of the bifidobacteria cell powder using the gelatinized starch suspension as a control also showed a normal distribution.
When observed with an optical microscope, the bifidobacteria cell powder of the present invention consists of almost spherical particles, and is observed when the dried powder is mechanically micronized by a method that does not prepare droplets such as freeze-drying. It did not contain any linear, irregular crushed material. Furthermore, when the bacterial cell powder was observed with a polarizing microscope, a characteristic cross (interference ring) indicating that starch was not gelatinized could be seen. The bifidobacterial cell powder using the gelatinized starch suspension as a control has almost the same shape as that of the present invention, but a cross (interference ring) could not be seen.

ビフィドバクテリウム・ロンガムFERM P-10657株を、乳糖を最終濃度で1%となるように添加したBL培地(光岡知足編、ビフィズス菌の研究、日本ビフィズス菌センター刊、1994)に接種し、NaOH水でpH6.0に保持しながら、37℃、16時間培養した。培養物を遠心分離機にて20倍濃縮した。この培養濃縮液に同量の糊化していない10%馬鈴薯デンプン懸濁液を25℃で糊化しないように懸濁・混合し、噴霧乾燥機にて入口温度125℃、出口温度60℃で噴霧乾燥し本発明のビフィズス菌菌体粉末を得た。コントロールとして、培養濃縮液に70℃で混合して糊化させた同量の10%馬鈴薯デンプン懸濁液と混合し、噴霧乾燥機にて同一条件で噴霧乾燥してビフィズス菌菌体粉末を得た。本発明のビフィズス菌菌体粉末中の生菌数は8.5×1011個/g、コントロールは1.6×1011個/gであり、糊化していないデンプン懸濁液と混合した本発明の菌体の生残率が、糊化したデンプン懸濁液を用いたビフィズス菌粉末より5倍以上高かった。
本発明のビフィズス菌菌体粉末を、光学顕微鏡で観察した場合、ほぼ球形の粒子のみからなっており、線状の不定形な破砕物は含まれていなかった。さらに、菌体粉末を偏光顕微鏡で観察すると、デンプンが糊化していないことを示す特徴的な十字(干渉輪)を見ることができた。
コントロールとして、糊化したデンプン懸濁液を用いたビフィズス菌菌体粉末は、形状は本発明のものとほぼ同じであるが、十字(干渉輪)を見ることができなかった。
Bifidobacterium longum FERM P-10657 strain is inoculated into BL medium (Mitsuoka Chichiho, Bifidobacterium research, published by Japan Bifidobacteria Center, 1994) supplemented with lactose to a final concentration of 1%, While maintaining the pH at 6.0 with NaOH water, the cells were cultured at 37 ° C. for 16 hours. The culture was concentrated 20 times in a centrifuge. Suspend and mix the same amount of non-gelatinized 10% potato starch suspension at 25 ° C in this culture concentrate so that it will not gelatinize at 25 ° C, and spray it with a spray dryer at an inlet temperature of 125 ° C and an outlet temperature of 60 ° C. It dried and the bifidobacteria cell powder of this invention was obtained. As a control, it is mixed with the same amount of 10% potato starch suspension mixed and gelatinized at 70 ° C in the culture concentrate, and spray-dried under the same conditions in a spray dryer to obtain a Bifidobacterium cell powder. It was. The number of viable cells in the Bifidobacterium cell powder of the present invention is 8.5 × 10 11 cells / g, the control is 1.6 × 10 11 cells / g, and the cell of the present invention mixed with an ungelatinized starch suspension The survival rate was more than 5 times higher than the bifidobacteria powder using the gelatinized starch suspension.
When the bifidobacteria cell powder of the present invention was observed with an optical microscope, it consisted only of substantially spherical particles and did not contain linear, irregularly crushed material. Furthermore, when the cell powder was observed with a polarizing microscope, a characteristic cross (interference ring) indicating that starch was not gelatinized could be seen.
As a control, the bifidobacteria cell powder using the gelatinized starch suspension had almost the same shape as that of the present invention, but a cross (interference ring) could not be seen.

ビフィドバクテリウム・ロンガムFERM P-8743株を、乳糖を最終濃度で1%となるように添加したBL培地(光岡知足編、ビフィズス菌の研究、日本ビフィズス菌センター刊、1994)に接種し、NaOH水でpH6.0に保持しながら、37℃、16時間培養した。培養物を遠心分離機にて20倍濃縮した。この培養濃縮液に同量の糊化していない10%馬鈴薯デンプン懸濁液を25℃で糊化しないように懸濁・混合し、噴霧乾燥機にて入口温度125℃、出口温度60℃で噴霧乾燥し本発明のビフィズス菌菌体粉末を得た。コントロールとして、培養濃縮液に70℃で混合して糊化させた同量の10%馬鈴薯デンプン懸濁液を混合して噴霧乾燥機にて同一条件で噴霧乾燥してビフィズス菌菌体粉末を得た。本発明のビフィズス菌菌体粉末中の生菌数は8.7×1011個/g、コントロールは5.9×1011個/gであり、糊化していないデンプンと混合した本発明の菌体粉末の生残率が、糊化したデンプンを用いたビフィズス菌菌体粉末より1.4倍以上高かった。
本発明のビフィズス菌菌体粉末を、光学顕微鏡で観察した場合、ほぼ球形の粒子のみからなっており、線状の不定形な破砕物は含まれていなかった。さらに、本発明のビフィズス菌菌体粉末を偏光顕微鏡で観察するとデンプンが糊化していないことを示す特徴的な十字(干渉輪)を見ることができた。コントロールとして糊化したデンプンを用いたビフィズス菌菌体粉末は、形状は本発明のものとほぼ同じであるが、十字(干渉輪)を見ることができなかった。
Bifidobacterium longum FERM P-8743 strain is inoculated into BL medium (Mitsuoka Chitoshi, Bifidobacterium research, published by Japan Bifidobacteria Center, 1994) supplemented with lactose to a final concentration of 1%, While maintaining the pH at 6.0 with NaOH water, the cells were cultured at 37 ° C. for 16 hours. The culture was concentrated 20 times in a centrifuge. Suspend and mix the same amount of non-gelatinized 10% potato starch suspension at 25 ° C in this culture concentrate so that it will not gelatinize at 25 ° C, and spray it with a spray dryer at an inlet temperature of 125 ° C and an outlet temperature of 60 ° C. It dried and the bifidobacteria cell powder of this invention was obtained. As a control, the same amount of 10% potato starch suspension mixed and gelatinized with the culture concentrate at 70 ° C was mixed and spray-dried under the same conditions in a spray dryer to obtain a Bifidobacterium cell powder. It was. The viable cell count in the Bifidobacterium cell powder of the present invention is 8.7 × 10 11 cells / g, the control is 5.9 × 10 11 cells / g, and the cell powder of the present invention mixed with non-gelatinized starch is viable. The residual rate was 1.4 times higher than the bifidobacteria cell powder using gelatinized starch.
When the bifidobacteria cell powder of the present invention was observed with an optical microscope, it consisted only of substantially spherical particles and did not contain linear, irregularly crushed material. Furthermore, when the Bifidobacterium cell powder of the present invention was observed with a polarizing microscope, a characteristic cross (interference ring) indicating that starch was not gelatinized could be seen. The bifidobacteria cell powder using gelatinized starch as a control has almost the same shape as that of the present invention, but a cross (interference ring) could not be seen.

実施例1で得られたビフィズス菌菌体粉末50g、ラクトース140g、シュガーエステル8g、カルボキシメチルセルロース2gを混合し、圧縮錠剤製造機(y-5010-Q、富士薬品機械社製)により圧縮(条件2〜3ton)して、錠剤を製造した。   50 g of bifidobacteria powder obtained in Example 1, 140 g of lactose, 8 g of sugar ester, and 2 g of carboxymethylcellulose were mixed and compressed by a compressed tablet manufacturing machine (y-5010-Q, manufactured by Fuji Yakuhin Kikai Co., Ltd.) ˜3 tons) to produce tablets.

ビタミンCとクエン酸の等量混合物40g、グラニュー糖45g、コーンスターチと乳糖の等量混合物60gに、実施例2で得られたビフィズス菌菌体粉末40gを加えて混合した。混合物をスティック状の袋に詰め、1袋1.5gの栄養健康食品を製造した。   40 g of bifidobacteria cell powder obtained in Example 2 was added to and mixed with 40 g of an equal mixture of vitamin C and citric acid, 45 g of granulated sugar, and 60 g of an equal mixture of corn starch and lactose. The mixture was packed in a stick-shaped bag to produce 1.5 g of nutritional health food per bag.

実施例1で得られたビフィズス菌菌体粉末0.1%とラクトバチルス・アシドフィルスの脱脂乳培養物1%をヨーグルトミックス(生乳に脱脂粉乳を2%添加し、100℃、10分間加熱した)に接種し、紙カップに充填後、37℃で6時間培養し、発酵乳を調製した。   Inoculate yogurt mix (2% skim milk powder added to raw milk, heated at 100 ° C for 10 minutes) with 0.1% bifidobacteria powder obtained in Example 1 and 1% Lactobacillus acidophilus skim milk culture Then, after filling into a paper cup, it was cultured at 37 ° C. for 6 hours to prepare fermented milk.

収穫したアルファルファ材料草を軽く乾燥し、マウントカッターで15〜25mmに切断し、実施例2で得られたビフィズス菌菌体粉末1部とラクトバチルス・アシドフィルスの培養物粉末5部とを混合し、この菌体混合物を材料草1gあたり105 cfuとなるように接種した。ポリサイロを30℃で10日間貯蔵して、サイレージを調製した。 The harvested alfalfa material grass is lightly dried, cut into 15 to 25 mm with a mount cutter, and 1 part of the bifidobacteria cell powder obtained in Example 2 and 5 parts of the Lactobacillus acidophilus culture powder are mixed, This bacterial cell mixture was inoculated at 10 5 cfu per 1 g of material grass. Polysilos were stored at 30 ° C. for 10 days to prepare silage.

実施例1で得られたビフィズス菌菌体粉末(本発明品)及び糊化したデンプンを用いたビフィズス菌菌体粉末(コントロール品)の粒子径分布を示す。The particle size distribution of the bifidobacteria cell powder (invention product) obtained in Example 1 and the bifidobacteria cell powder (control product) using gelatinized starch is shown.

Claims (3)

糊化していないデンプンを含有し、不定形のデンプン破砕物を含有しないことを特徴とする、生残性の良好なビフィズス菌菌体粉末。   Bifidobacteria powder having good survival characteristics, characterized by containing non-gelatinized starch and not containing irregularly shaped starch crushed material. 請求項1記載のビフィズス菌菌体粉末を含有した飲食品または飼料。   The food-drinks or feed containing the bifidobacteria cell powder of Claim 1. ビフィズス菌の培養液と、糊化していないデンプンの粉末または懸濁液とを、デンプンが糊化しないように混合して懸濁液とし、この懸濁液を噴霧乾燥することを特徴とするビフィズス菌菌体粉末の製造法。   A bifidobacteria characterized by mixing a culture solution of bifidobacteria and a non-gelatinized starch powder or suspension so that the starch is not gelatinized, and then spray-drying the suspension. Manufacturing method of fungus body powder.
JP2005103714A 2005-03-31 2005-03-31 Bacillus bifidus cell powder Pending JP2006280263A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005103714A JP2006280263A (en) 2005-03-31 2005-03-31 Bacillus bifidus cell powder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005103714A JP2006280263A (en) 2005-03-31 2005-03-31 Bacillus bifidus cell powder

Publications (1)

Publication Number Publication Date
JP2006280263A true JP2006280263A (en) 2006-10-19

Family

ID=37402809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005103714A Pending JP2006280263A (en) 2005-03-31 2005-03-31 Bacillus bifidus cell powder

Country Status (1)

Country Link
JP (1) JP2006280263A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972208A1 (en) 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition for improving intestinal microflora
WO2011075138A1 (en) * 2009-12-18 2011-06-23 Hill's Pet Nutrition, Inc. Pet food compositions including probiotics and methods of manufacture and use thereof
WO2011114182A1 (en) * 2010-03-17 2011-09-22 Compagnie Gervais Danone Dried fermented dairy product containing a high density of living bifidobacteria
JP2016074615A (en) * 2014-10-03 2016-05-12 富士カプセル株式会社 Trilaminar structure seamless capsule
JP2017534245A (en) * 2014-08-06 2017-11-24 エンヴェラ エルエルシー Bacterial spore composition for industrial use
JP2019034974A (en) * 2018-12-05 2019-03-07 富士カプセル株式会社 Trilaminar structure seamless capsule

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58149675A (en) * 1982-03-03 1983-09-06 Meiji Milk Prod Co Ltd Preparation of powder containing active bifidus bacteria
WO1986005094A1 (en) * 1985-03-08 1986-09-12 Takeda Chemical Industries, Ltd. Antiobesity agent and composition
JPS63251080A (en) * 1987-04-09 1988-10-18 Yakult Honsha Co Ltd Production of powder containing cell of bifidobacterium
JPH04273823A (en) * 1991-02-27 1992-09-30 Nisshin Flour Milling Co Ltd Bifidobacterium bacterium preparation and production thereof
JP2002017337A (en) * 2000-05-02 2002-01-22 Biofuerumin Seiyaku Kk Dried microbial cell by spray-drying
JP2002511403A (en) * 1998-03-27 2002-04-16 ヴァルション テクニッリネン トゥトキムスケスクス Starch capsule containing microorganism and / or polypeptide or protein, and method for producing the same
US20040175389A1 (en) * 2003-01-14 2004-09-09 Porubcan Randolph Stanley Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life
JP2005052100A (en) * 2003-08-06 2005-03-03 Shuichi Shiomi Dried material of lactic acid bacterium and method for producing the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58149675A (en) * 1982-03-03 1983-09-06 Meiji Milk Prod Co Ltd Preparation of powder containing active bifidus bacteria
WO1986005094A1 (en) * 1985-03-08 1986-09-12 Takeda Chemical Industries, Ltd. Antiobesity agent and composition
JPS63251080A (en) * 1987-04-09 1988-10-18 Yakult Honsha Co Ltd Production of powder containing cell of bifidobacterium
JPH04273823A (en) * 1991-02-27 1992-09-30 Nisshin Flour Milling Co Ltd Bifidobacterium bacterium preparation and production thereof
JP2002511403A (en) * 1998-03-27 2002-04-16 ヴァルション テクニッリネン トゥトキムスケスクス Starch capsule containing microorganism and / or polypeptide or protein, and method for producing the same
JP2002017337A (en) * 2000-05-02 2002-01-22 Biofuerumin Seiyaku Kk Dried microbial cell by spray-drying
US20040175389A1 (en) * 2003-01-14 2004-09-09 Porubcan Randolph Stanley Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life
JP2005052100A (en) * 2003-08-06 2005-03-03 Shuichi Shiomi Dried material of lactic acid bacterium and method for producing the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INT. J. FOOD MICROBIOL., vol. 86(2003), JPN6011001103, pages 293 - 301, ISSN: 0001822029 *
J.APPL.MICROBIOL.,VOL.91,NO.6(2001)P.1059-1066, JPN6011041964, ISSN: 0001992464 *
糖質の科学, JPN6011001104, 1996, pages 51, ISSN: 0001822030 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972208A1 (en) 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition for improving intestinal microflora
WO2011075138A1 (en) * 2009-12-18 2011-06-23 Hill's Pet Nutrition, Inc. Pet food compositions including probiotics and methods of manufacture and use thereof
US11510424B2 (en) 2009-12-18 2022-11-29 Hill's Pet Nutrition, Inc. Pet food compositions including probiotics and methods of manufacture and use thereof
US10212954B2 (en) 2009-12-18 2019-02-26 Colgate-Palmolive Company Pet food compositions including probiotics and methods of manufacture and use thereof
RU2533024C2 (en) * 2009-12-18 2014-11-20 Хилл`С Пет Ньютришн, Инк. Feed stuff compositions for domestic animals containing probiotics, methods for producing and using them
JP2013514085A (en) * 2009-12-18 2013-04-25 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Pet food compositions containing probiotics and methods of preparing and using the same
CN103619183A (en) * 2010-03-17 2014-03-05 热尔韦·达诺尼公司 Dried fermented dairy product containing a high density of living bifidobacteria
US20130011517A1 (en) * 2010-03-17 2013-01-10 Philippe Teissier Dried fermented dairy product containing a high density of living bifidobacteria
EA028428B1 (en) * 2010-03-17 2017-11-30 Компани Жервэ Данон Dried fermented dairy product containing a high density of living bifidobacteria
WO2011113771A1 (en) * 2010-03-17 2011-09-22 Compagnie Gervais Danone Dried fermented dairy product containing a high density of living bifidobacteria
WO2011114182A1 (en) * 2010-03-17 2011-09-22 Compagnie Gervais Danone Dried fermented dairy product containing a high density of living bifidobacteria
JP2017534245A (en) * 2014-08-06 2017-11-24 エンヴェラ エルエルシー Bacterial spore composition for industrial use
JP2016074615A (en) * 2014-10-03 2016-05-12 富士カプセル株式会社 Trilaminar structure seamless capsule
JP2019034974A (en) * 2018-12-05 2019-03-07 富士カプセル株式会社 Trilaminar structure seamless capsule

Similar Documents

Publication Publication Date Title
US6841181B2 (en) Encapsulated multifunctional biologically active food component, process for its production and its use
CA2825011C (en) Microencapsulated probiotic substance and process of manufacture
CN105996051B (en) Comprising lactic acid bacteria and protection novel compositions of agents
EP2117354B1 (en) A dry food product containing live probiotic
JP3363438B2 (en) Dried bacterial cells by spray drying
CN108368474B (en) Stable dry compositions with little or no sugar
CA2538676A1 (en) Probiotic storage and delivery
MX2011001428A (en) Production of beadlets comprising probiotic compounds.
Das et al. Microencapsulation of probiotic bacteria and its potential application in food technology
JP2006280263A (en) Bacillus bifidus cell powder
Lai et al. Microencapsulation of Lactobacillus plantarum 299v and its storage in kuini juice.
US20150071891A1 (en) Pre-fermented symbiotic matrix based on a cereal suspension with encapsulated probiotics, manufacture process and corresponding utilization
JP3824312B2 (en) Dried bacterial cells by spray drying
RU2721127C1 (en) Lactobacillus salivarius cjls1511, fodder additive composition for animals containing said bacterium or dead cells thereof, and method of producing said dead cells
CN110251474B (en) Preparation method of starch-based large intestine targeting double-layer probiotic tablet
JPWO2020158737A1 (en) A probiotic composition imparting storage stability and gastric fluid decomposition resistance stability.
CN112293605A (en) EP puffed fermented compound feed with effects of promoting digestion, immunocompetence and growth of fish and preparation method thereof
Kaewiad et al. Statistical optimization of bambara groundnut protein isolate-alginate matrix systems on survival of encapsulated Lactobacillus rhamnosus GG
JPH0367552A (en) Stable spore-forming variable cell drug, production thereof and pellet

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080228

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110311

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20110725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120201